NCT05025735: Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 65 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have had prior treatment with a CDK4/6 inhibitor (e.g. palbociclib/Ibrance, abemaciclib/Verzenio, ribociclib/Kisqali)
Exclusions: Patients who have received prior treatment with chemotherapy, fulvestrant, any PI3K, mTOR or AKT inhibitor (e.g. Piqray/alpelisib, Afinitor/everolimus) in the metastatic setting; Patients with untreated unstable symptomatic brain metastases – see trial for details

Comments are closed.

Up ↑